What was the market valuation of the South Korea hematopoietic stem-cell-transplantation market in 2024?

The market valuation was $98.09 Million in 2024. Read More

What is the projected market valuation for the South Korea hematopoietic stem-cell-transplantation market by 2035?

The projected valuation for 2035 is $348.76 Million. Read More

Which companies are considered key players in the South Korea hematopoietic stem-cell-transplantation market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda, Roche, Merck, and AstraZeneca. Read More

What were the valuations for allogeneic and autologous transplants in 2024?

Both allogeneic and autologous transplants were valued at $49.05 Million and $49.04 Million, respectively. Read More

How do the valuations for acute myeloid leukemia and acute lymphoblastic leukemia compare in 2024?

Acute myeloid leukemia was valued at $20.0 Million, while acute lymphoblastic leukemia was valued at $15.0 Million. Read More

What was the valuation for peripheral blood stem cell transplants in 2024?

The valuation for peripheral blood stem cell transplants was $40.0 Million in 2024. Read More

What is the projected growth for non-Hodgkin lymphoma treatment in the South Korea hematopoietic stem-cell-transplantation market?

The projected valuation for non-Hodgkin lymphoma is expected to reach $90.0 Million by 2035. Read More

What were the valuations for bone marrow transplants and cord blood transplants in 2024?

Bone marrow transplants were valued at $30.0 Million, while cord blood transplants were valued at $28.09 Million. Read More

South Korea Hematopoietic Stem Cell Transplantation Market

Q: What is the expected CAGR for the South Korea hematopoietic stem-cell-transplantation market during the forecast period 2025 - 2035?

The expected CAGR during this period is 12.22%. Read More

Q: What is the expected trend for the South Korea hematopoietic stem-cell-transplantation market in the coming years?

The market is likely to experience substantial growth, reaching $348.76 Million by 2035. Read More

ID: MRFR/LS/48277-HCR

200 Pages

Nidhi Mandole

Last Updated: April 24, 2026

South Korea Hematopoietic Stem Cell Transplantation Market Research Report By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Application (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth & Industry Forecast 2025 To 2035

South Korea Hematopoietic Stem Cell Transplantation Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Transplant Type (USD Million)
  1. 4.1.1 Allogeneic
  2. 4.1.2 Autologous
2. 4.2 Healthcare, BY Indication (USD Million)
  1. 4.2.1 Acute Myeloid Leukemia
  2. 4.2.2 Acute Lymphoblastic Leukemia
  3. 4.2.3 Hodgkin Lymphoma
  4. 4.2.4 Non-Hodgkin Lymphoma
  5. 4.2.5 Multiple Myeloma
  6. 4.2.6 Other Non-Malignant Disorders
3. 4.3 Healthcare, BY Application (USD Million)
  1. 4.3.1 Bone Marrow Transplant
  2. 4.3.2 Peripheral Blood Stem Cells Transplant
  3. 4.3.3 Cord Blood Transplant
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Celgene (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TRANSPLANT TYPE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY INDICATION
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF HEALTHCARE
8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
11. 6.11 HEALTHCARE, BY TRANSPLANT TYPE, 2024 (% SHARE)
12. 6.12 HEALTHCARE, BY TRANSPLANT TYPE, 2024 TO 2035 (USD Million)
13. 6.13 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TRANSPLANT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Healthcare Market Segmentation

Healthcare By Transplant Type (USD Million, 2025-2035)

Allogeneic
Autologous

Healthcare By Indication (USD Million, 2025-2035)

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Other Non-Malignant Disorders

Healthcare By Application (USD Million, 2025-2035)

Bone Marrow Transplant
Peripheral Blood Stem Cells Transplant
Cord Blood Transplant

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”